Jaguar Health, Inc. (JAGX) - Q1 2026 Filing Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended March 31, 2026. Jaguar Health, Inc. operates in two segments: Human Health (focused on crofelemer-based products like Mytesi and development of orphan drugs for intestinal failure) and Animal Health (focused on gastrointestinal products for companion animals). The company is a smaller reporting company listed on the Nasdaq Capital Market.
Key Financial Metrics
| Metric | Q1 2026 | Q1 2025 |
|---|---|---|
| Total Revenue | $20.3 million | $2.2 million |
| Net Income (Loss) | $8.7 million | $(10.6) million |
| Net Loss Attributable to Common Stockholders | $(7.0) million | $(10.5) million |
| Operating Income (Loss) | $10.2 million | $(9.4) million |
| Cash and Restricted Cash | $10.1 million | $5.7 million |
| Total Debt (Notes Payable) | $33.2 million | $42.5 million |
| Stockholders' Deficit | $(15.8) million | $(18.7) million |
Note: Net income was significantly impacted by a $19.0 million license revenue recognition. Net loss attributable to common stockholders remains negative due to preferred stock dividends and returns.
Material Changes vs. Prior Period
- Revenue Surge: Total revenue increased 816% year-over-year, driven primarily by a $19.0 million license fee recognized from a January 2026 agreement with Woodward (an affiliate of Future Pak) for the exclusive US rights to Mytesi and Canalevia. Product revenue declined 45% to $1.2 million due to lower Mytesi sales volumes.
- Profitability Turnaround: The company reported a net income of $8.7 million compared to a net loss of $10.6 million in Q1 2025. Operating income swung from a $9.4 million loss to a $10.2 million gain.
- Debt Reduction: Total notes payable decreased by approximately $9.3 million due to cash repayments and debt-for-equity exchanges. The company settled portions of convertible notes and royalty interests.
- Liquidity Improvement: Cash and restricted cash increased to $10.1 million from $5.7 million, bolstered by the upfront license fee. However, $2.8 million of this is restricted cash held as collateral for a secured promissory note.
Guidance, Outlook, Risks, and Unusual Items
- Going Concern Warning: Management explicitly states that conditions raise substantial doubt about the company's ability to continue as a going concern for one year from the issuance date. While the $16.0 million upfront license fee improved liquidity, the company does not have sufficient cash to fund its operating plan for the next 12 months without additional financing.
- Nasdaq Compliance Risks: The company faced delisting notices regarding the Bid Price Rule (stock price below $1.00) and the Publicly Held Shares Requirement (dropped below 500,000 shares after a reverse split). Subsequent events indicate the company regained compliance with the share count requirement via warrant exercises and received an extension to demonstrate bid price compliance by May 18, 2026.
- Unusual Items:
- License Revenue: $19.0 million recognized from the Woodward agreement.
- Debt Extinguishment Loss: $0.6 million loss recorded due to significant modifications of debt instruments.
- Preferred Stock Dividends: Significant non-cash charges for stock dividends ($9.5 million) and deemed dividends ($6.1 million) to preferred stockholders reduced net income available to common shareholders.
- Outlook: The company plans to submit a clinical study report for the OnTarget trial and pursue a new pivotal trial for metastatic breast cancer. It continues to develop crofelemer powder for oral solution for MVID and SBS-IF.
Investor Verification Checklist
- Going Concern Status: Verify the company's ability to secure additional financing beyond the current cash balance to sustain operations for the next 12 months.
- Nasdaq Listing Status: Confirm the company maintains compliance with the $1.00 bid price requirement and the 500,000 publicly held shares requirement following the recent reverse stock split.
- Revenue Sustainability: Assess the sustainability of revenue streams post the one-time $19.0 million license fee, given the decline in product sales.
- Debt Structure: Review the terms of the remaining royalty interests and secured notes, particularly the collateral requirements and potential for further debt-for-equity exchanges.
- Preferred Stock Dilution: Monitor the impact of preferred stock dividends and conversions on the equity available to common shareholders.